Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03851250 · ClinicalTrials.gov registry record · Phase 1
A Study of MRx-4DP0004 in Asthma
A Phase 1 study, sponsored by 4D pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03851250: Clinical Trial Phase 1 study, sponsored by 4D pharma.
NCT03851250 is a Phase 1 study that was terminated before completion, run by 4D pharma. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03851250, a Phase 1 study, was terminated before completion, sponsored by 4D pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma. Participants will take two capsules of MRx-4DP0004 twice daily in addition to their existing asthma medication for 12 weeks. Safety and tolerability and immune modulatory effects of MRx-4DP0004 will be assessed throughout the study.
Primary Outcome
Adverse events will be considered alongside other primary outcome measures for assessment of safety and tolerability.
Interventions
- DRUG Placebo
- DRUG MRx-4DP0004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-07-04 |
| Est. Completion | 2023-04-26 |
| Phase | Phase 1 |
Why NCT03851250 stopped before completion
NCT03851250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03851250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03851250 about?
NCT03851250 is a clinical study titled "A Study of MRx-4DP0004 in Asthma". This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma. Participants will take two capsules of MRx-4DP0004 twice daily in addition to their existing asthma medication for 12 weeks. Safety and tolerability and im...
What is the current status of trial NCT03851250?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2019-07-04. Estimated completion is 2023-04-26.
What interventions are being tested in trial NCT03851250?
The interventions under investigation include: Placebo (DRUG), MRx-4DP0004 (DRUG).
Who is sponsoring clinical trial NCT03851250?
This trial is sponsored by 4D pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03851250's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI